Home › Therapeutic areas › Neurology › Multiple Sclerosis

Multiple Sclerosis (17 companies)

Companies with an active program in Multiple Sclerosis.

Ticker Company Therapeutic areas Programs Lead stage Mkt cap Programs
ALMS Alumis DermatologyImmunology+1 1 Phase 3 $628M 5
AUTL Autolus Therapeutics HematologyImmunology+3 Rare 1 Approved $290M 12
CLNN Clene Neurology Rare 1 NDA Submitted $46.4M 5
CTNM Contineum Therapeutics NeurologyRespiratory Rare 1 Phase 2 $375M 4
HRMY Harmony Biosciences MetabolicNeurology Rare 1 Approved $1.94B 17
IMUX Immunic GI/HepatologyNeurology 2 Phase 3 $116M 4
KYTX Kyverna Therapeutics ImmunologyNeurology+1 Rare 1 NDA Submitted $297M 6
NRXP NRX Pharmaceuticals Neurology Rare 1 Approved $109M 11
NRIX Nurix Therapeutics ImmunologyNeurology+1 1 Phase 3 $1.56B 13
OCS Oculis Holding NeurologyOphthalmology Rare 1 Phase 3 $418M 5
DTIL Precision Biosciences Infectious DiseaseMetabolic+1 Rare 1 Phase 1 $197M 5
PCSA Processa Pharmaceuticals GI/HepatologyImmunology+2 Rare 1 Phase 2 $4.8M 7
TGTX Tg Therapeutics Neurology Rare 3 Approved $9.48B 6
TLSA Tiziana Life Sciences ImmunologyNeurology Rare 1 Phase 2 $83.2M 5
VNDA Vanda Pharmaceuticals CardiovascularDermatology+6 Rare 1 Approved $230M 27
XNCR Xencor ImmunologyNeurology+1 Rare 1 Approved $2.59B 28
ZBIO Zenas BioPharma DermatologyImmunology+2 Rare 3 NDA Submitted $1.88B 11